Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ntx-NTC
- Development stage
- Preclinical
- Lead developer
- Northwestern University
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intrathecal
01
Overview
Ntx-NTC is a non-targeting control (NTC) agent designed for preclinical research in central nervous system (CNS) disorders, such as epilepsy and glioblastoma. It consists of a non-targeting small interfering RNA (siRNA) sequence conjugated to the 'Ntx' platform, a novel lipid-conjugate delivery system that enables widespread distribution throughout the CNS following intrathecal administration. Ntx-NTC is used as a negative control for Ntx-DBI, a therapeutic candidate that targets Diazepam Binding Inhibitor (DBI) to treat drug-refractory epilepsy and inhibit gliomagenesis. By serving as a comparator, Ntx-NTC allows researchers to isolate the specific therapeutic effects of DBI knockdown from the baseline effects of the delivery vehicle and the administration of exogenous RNA.
- Other names
- Ntx-nontargeting control
Beyond the preview
Go deeper on Ntx-NTC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ntx-NTC.